Marksans Pharma Ltd Share Price Today - Marksans Pharma Ltd Stock Price Live NSE/BSE

Marksans Pharma Ltd

NSE: MARKSANS BSE: 524404

₹172.95

(-0.64%)

Wed, 18 Mar 2026, 04:53 pm

MTF 5xInvest in Marksans Pharma Ltd with 5x Leverage Buy with MTF

Market Cap78.85B

PE Ratio21.75

Dividend0.46

Health Technology

Pharmaceuticals: Major

24.5K

Marksans Pharma Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
7436.42
Net Profit
382.62
P/B
4.08
Sector P/E
31.82
P/E
26.47
EV/EBITDA
16.18
Debt/Equity (Industry)
0.25
Interest Cover (Industry)
11.42
ROCE (Industry)
16.55
RONW (Industry)
14.50
ROE
16.89
ROCE
20.19
Debt/Equity
0.12
EPS (TTM)
7.95
Dividend Yield
0.49
Book Value
59.32
Interest Cover
44.22

Analysis

all

Pros

Marksans Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Marksans Pharma is profitable, therefore cash runway is not a concern.
Marksans Pharma is profitable, therefore cash runway is not a concern.
Debt is well covered by operating cash flow (880.5%, greater than 20% of total debt).
Debt is covered by short term assets, assets are 24.8x debt.

Cons

Marksans Pharma is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
No need to calculate the sustainability of Marksans Pharma's dividends as it is not paying a notable one for India.
Marksans Pharma is not paying a notable dividend for India, therefore no need to check if the payments are stable.
Marksans Pharma's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Marksans Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	43.87	43.87	43.87	43.87	43.87
FII	8.12	16.92	19.88	22.20	21.96
DII	5.91	5.28	5.50	4.56	4.30
Public	42.09	33.93	30.75	29.37	29.87
Government	0	0	0	0	0

Technical Analysis

RSI

43.11

MACD

-2.68

50 DMA

173.85

200 DMA

195.64

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	236.02	205.89	189.91	175.76	159.78	145.63	115.50
Fibonacci	205.89	194.38	187.27	175.76	164.25	157.14	145.63
Camarilla	182.22	179.45	176.69	175.76	171.17	168.41	165.64

Pivots Level: Classic

+60.26

236.02

+30.13

205.89

+14.15

189.91

175.76

Pivot Point

LTP: 167.89

-15.98

159.78

-30.13

145.63

-60.26

115.50

Moving Average

SMAEMA

Period

Value

10-EMA
169.25
20-EMA
171.67
30-EMA
173.02
50-EMA
174.92
100-EMA
180.05
200-EMA
191.61

Announcement Date	Purpose	Action	Ex Date
05 Feb 2026	board-meetings	Quarterly Results
13 Nov 2025	board-meetings	Quarterly Results, Nine Months Results
11 Jul 2025	agm
01 Jul 2025	dividend	Final Dividend - Rs. - 0.8	01 Aug 2025
19 May 2025	dividend	₹0.80 Dividend /Share	01 Aug 2025
19 Aug 2024	agm
17 Aug 2024	dividend	Final Dividend - Rs. - 0.6	17 Sept 2024
30 May 2024	dividend	₹0.60 Dividend /Share	17 Sept 2024
02 Aug 2023	agm
30 May 2023	dividend	₹0.50 Dividend /Share	07 Jun 2023

Marksans Pharma Ltd

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd

Lupin Ltd

Sun Pharmaceutical Industries Ltd

Marksans Pharma Ltd About

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. It operates two manufacturing facilities in Goa and maintains two R&D centers, one located in Goa and the other in Navi Mumbai.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1992

Headquarters

CEO

Mark Saldanha

Employees

Contact

Website

http://www.marksanspharma.com

companysecretary@marksanspharma.com ; info@marksan

Phone

91-22-40012000

Location

11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W), Mumbai, Maharashtra, 400053

Year	History
2017	Marksans Pharma Goa plant received UK MHRA approval. Marksans Pharma received certificate of GMP Compliance of a Manufacturer from Australian government, Department of Health, Therapeutic Goods Administration.
2021	Marksans Pharma received USFDA approval for Acetaminophen ER Tablets.
2022	The company completed the process of acquiring 100% share capital of Access Healthcare for Medical Products LLC based in Dubai, UAE. Marksans Pharma received USFDA approval for Cetirizine Hydrochloride Tablets. Marksans Pharma received UK MHRA approval for Bells Healthcare All in One Oral Solution.
2023	Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited received Marketing Authorisation for Cyanocobalamin 50mg film coated tablets. Marksans Pharma completed the acquisition from Tevapharm India, expanding the existing manufacturing capacity in India. Marksans Pharma received UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution.
2024	Marksans Pharma Limited receives USFDA approval for Loratadine Tablets USP 10mg. US FDA Inspection at Marksans Pharma's manufacturing facility located at Verna, Goa was successfully closed.

Client Name	Order Side	QTY	Avg Price	Date
UNIFI CAPITAL PRIVATE LIMITED	Buy	7241309	231.5	28 Jul 2025
UNIFI CAPITAL PRIVATE LIMITED -BLENDED RANGOLI	Buy	3247600	249.95	11 Jun 2025
ORBIMED ASIA IV MAURITIUS FVCI LIMITED	Sell	10273443	249.95	11 Jun 2025
UNIFI BLEND FUND 2	Buy	3000000	249.95	11 Jun 2025
VANGUARD EMERGING MARKETS STOCK INDEX FUND A SERIES OF VANGUARD INTERNATIONAL EQUITY INDEX FUNDS	Buy	2301640	316.85	20 Sept 2024
VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND	Buy	2697280	316.85	20 Sept 2024
GRAVITON RESEARCH CAPITAL LLP	Sell	2451180	305.27	20 Sept 2024
UBS PRINCIPAL CAPITAL ASIA LIMITED	Sell	3401630	317.22	20 Sept 2024
GRAVITON RESEARCH CAPITAL LLP	Buy	2451180	305.27	20 Sept 2024
MASSACHUSETTS INSTITUTE OF TECHNOLOGY	Buy	6600000	158	15 Apr 2024

Marksans Pharma Ltd News

Marksans Pharma Opens Special Window for Share Transfer

Marksans Pharma announces SEBI-mandated special window for re-lodgment of physical share transfer requests from pre-April 2019 transactions, valid from February 5, 2026 to February 4, 2027.

11 Mar 2026

stocks

Marksans Pharma Q3 FY26 Revenue Hits All-Time High

Marksans Pharma reported record Q3 FY26 operating revenue of INR 754.4 crores, up 10.6% YoY, with EBITDA growing 23.2% to INR 160.7 crores and margins expanding to 21.3%.

12 Feb 2026

co actions results

Marksans Pharma Q3 Net Profit Rises 7.6% YoY

Marksans Pharma reported consolidated net profit of ₹1.13 billion in Q3, marking a 7.6% increase from ₹1.05 billion in the same quarter last year.

05 Feb 2026

co actions results

Marksans Pharma Expands Global Footprint

Marksans Pharma establishes two fully owned subsidiaries in Ireland and Canada to strengthen its international pharmaceutical operations and market presence.

27 Jan 2026

stocks

Marksans Pharma Q3FY26 Earnings Call on Feb 6

Marksans Pharma has scheduled its Q3FY26 earnings conference call for February 6, 2026, at 4:00 PM IST to discuss unaudited financial results for quarter and nine months ended December 31, 2025.

22 Jan 2026

co actions results

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800